|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MTPN |
Gene summary for MTPN |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MTPN | Gene ID | 136319 |
| Gene name | myotrophin | |
| Gene Alias | GCDP | |
| Cytomap | 7q33 | |
| Gene Type | protein-coding | GO ID | GO:0001558 | UniProtAcc | P58546 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 136319 | MTPN | P32T-E | Human | Esophagus | ESCC | 3.45e-73 | 1.64e+00 | 0.1666 |
| 136319 | MTPN | P36T-E | Human | Esophagus | ESCC | 5.62e-31 | 9.56e-01 | 0.1187 |
| 136319 | MTPN | P37T-E | Human | Esophagus | ESCC | 3.88e-41 | 1.01e+00 | 0.1371 |
| 136319 | MTPN | P38T-E | Human | Esophagus | ESCC | 3.49e-09 | 4.93e-01 | 0.127 |
| 136319 | MTPN | P39T-E | Human | Esophagus | ESCC | 2.54e-17 | 5.58e-01 | 0.0894 |
| 136319 | MTPN | P40T-E | Human | Esophagus | ESCC | 5.13e-13 | 5.48e-01 | 0.109 |
| 136319 | MTPN | P42T-E | Human | Esophagus | ESCC | 4.97e-34 | 9.67e-01 | 0.1175 |
| 136319 | MTPN | P44T-E | Human | Esophagus | ESCC | 5.36e-21 | 7.39e-01 | 0.1096 |
| 136319 | MTPN | P47T-E | Human | Esophagus | ESCC | 2.50e-22 | 5.84e-01 | 0.1067 |
| 136319 | MTPN | P48T-E | Human | Esophagus | ESCC | 1.52e-15 | 3.58e-01 | 0.0959 |
| 136319 | MTPN | P49T-E | Human | Esophagus | ESCC | 2.23e-20 | 2.82e+00 | 0.1768 |
| 136319 | MTPN | P52T-E | Human | Esophagus | ESCC | 1.19e-22 | 7.35e-01 | 0.1555 |
| 136319 | MTPN | P54T-E | Human | Esophagus | ESCC | 8.13e-32 | 8.68e-01 | 0.0975 |
| 136319 | MTPN | P56T-E | Human | Esophagus | ESCC | 4.11e-08 | 1.01e+00 | 0.1613 |
| 136319 | MTPN | P57T-E | Human | Esophagus | ESCC | 8.94e-15 | 5.29e-01 | 0.0926 |
| 136319 | MTPN | P61T-E | Human | Esophagus | ESCC | 3.50e-17 | 5.46e-01 | 0.099 |
| 136319 | MTPN | P62T-E | Human | Esophagus | ESCC | 2.94e-42 | 6.99e-01 | 0.1302 |
| 136319 | MTPN | P65T-E | Human | Esophagus | ESCC | 8.45e-31 | 7.24e-01 | 0.0978 |
| 136319 | MTPN | P74T-E | Human | Esophagus | ESCC | 9.22e-46 | 1.42e+00 | 0.1479 |
| 136319 | MTPN | P75T-E | Human | Esophagus | ESCC | 1.42e-28 | 8.32e-01 | 0.1125 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
| GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
| GO:190290310 | Cervix | CC | regulation of supramolecular fiber organization | 92/2311 | 383/18723 | 1.49e-10 | 2.48e-08 | 92 |
| GO:003295610 | Cervix | CC | regulation of actin cytoskeleton organization | 86/2311 | 358/18723 | 5.90e-10 | 7.51e-08 | 86 |
| GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
| GO:004325410 | Cervix | CC | regulation of protein-containing complex assembly | 96/2311 | 428/18723 | 2.91e-09 | 3.05e-07 | 96 |
| GO:011005310 | Cervix | CC | regulation of actin filament organization | 67/2311 | 278/18723 | 4.01e-08 | 2.54e-06 | 67 |
| GO:005125810 | Cervix | CC | protein polymerization | 70/2311 | 297/18723 | 5.20e-08 | 3.11e-06 | 70 |
| GO:003227110 | Cervix | CC | regulation of protein polymerization | 57/2311 | 233/18723 | 2.37e-07 | 1.03e-05 | 57 |
| GO:00081549 | Cervix | CC | actin polymerization or depolymerization | 51/2311 | 218/18723 | 4.05e-06 | 1.05e-04 | 51 |
| GO:00510904 | Cervix | CC | regulation of DNA-binding transcription factor activity | 87/2311 | 440/18723 | 4.85e-06 | 1.22e-04 | 87 |
| GO:00712148 | Cervix | CC | cellular response to abiotic stimulus | 69/2311 | 331/18723 | 7.36e-06 | 1.73e-04 | 69 |
| GO:01040048 | Cervix | CC | cellular response to environmental stimulus | 69/2311 | 331/18723 | 7.36e-06 | 1.73e-04 | 69 |
| GO:00160498 | Cervix | CC | cell growth | 92/2311 | 482/18723 | 1.16e-05 | 2.49e-04 | 92 |
| GO:00300419 | Cervix | CC | actin filament polymerization | 45/2311 | 191/18723 | 1.20e-05 | 2.54e-04 | 45 |
| GO:00310996 | Cervix | CC | regeneration | 46/2311 | 198/18723 | 1.43e-05 | 2.84e-04 | 46 |
| GO:00325359 | Cervix | CC | regulation of cellular component size | 76/2311 | 383/18723 | 1.66e-05 | 3.21e-04 | 76 |
| GO:000641710 | Cervix | CC | regulation of translation | 89/2311 | 468/18723 | 1.86e-05 | 3.46e-04 | 89 |
| GO:19029048 | Cervix | CC | negative regulation of supramolecular fiber organization | 40/2311 | 167/18723 | 2.39e-05 | 4.17e-04 | 40 |
| GO:00096127 | Cervix | CC | response to mechanical stimulus | 48/2311 | 216/18723 | 3.23e-05 | 5.29e-04 | 48 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MTPN | SNV | Missense_Mutation | novel | c.7G>A | p.Asp3Asn | p.D3N | P58546 | protein_coding | tolerated(0.3) | possibly_damaging(0.649) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| MTPN | SNV | Missense_Mutation | novel | c.229T>G | p.Tyr77Asp | p.Y77D | P58546 | protein_coding | deleterious(0.01) | possibly_damaging(0.814) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| MTPN | SNV | Missense_Mutation | c.188N>A | p.Ala63Asp | p.A63D | P58546 | protein_coding | deleterious(0.05) | probably_damaging(0.988) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MTPN | SNV | Missense_Mutation | c.310G>A | p.Ala104Thr | p.A104T | P58546 | protein_coding | tolerated(0.34) | probably_damaging(0.934) | TCGA-BG-A0M7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD | |
| MTPN | SNV | Missense_Mutation | novel | c.147N>C | p.Glu49Asp | p.E49D | P58546 | protein_coding | tolerated(0.53) | benign(0.007) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MTPN | SNV | Missense_Mutation | c.18N>A | p.Phe6Leu | p.F6L | P58546 | protein_coding | tolerated(1) | benign(0.389) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MTPN | SNV | Missense_Mutation | novel | c.259N>A | p.Leu87Ile | p.L87I | P58546 | protein_coding | deleterious(0.01) | probably_damaging(0.982) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| MTPN | SNV | Missense_Mutation | c.13N>C | p.Glu5Gln | p.E5Q | P58546 | protein_coding | tolerated(0.1) | benign(0.214) | TCGA-60-2708-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
| MTPN | SNV | Missense_Mutation | novel | c.232G>A | p.Glu78Lys | p.E78K | P58546 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-KU-A6H7-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MTPN | SNV | Missense_Mutation | c.310N>A | p.Ala104Thr | p.A104T | P58546 | protein_coding | tolerated(0.34) | probably_damaging(0.934) | TCGA-HU-A4H2-01 | Stomach | stomach adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |